Difference between revisions of "GTS5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(2 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
− | |||
− | |||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Genetic Tumour Syndromes (5th Edition) Content</big> | |+<big>WHO Classification of Genetic Tumour Syndromes (5th Edition) Content</big> | ||
Line 38: | Line 36: | ||
| | | | ||
----<br /> | ----<br /> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|[[GTS5:Hereditary_papillary_renal_carcinoma_(MET)|Hereditary papillary renal carcinoma (MET)]] | |[[GTS5:Hereditary_papillary_renal_carcinoma_(MET)|Hereditary papillary renal carcinoma (MET)]] | ||
Line 400: | Line 127: | ||
|[[GTS5:Neurofibromatosis_type_1_(NF1)|Neurofibromatosis type 1 (NF1)]] | |[[GTS5:Neurofibromatosis_type_1_(NF1)|Neurofibromatosis type 1 (NF1)]] | ||
|Disease | |Disease | ||
+ | |Ngoni Faya (trainee) + Madina Sukhanova | ||
+ | |7/12/2023 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Madina Sukhanova (Madina S) | ||
| | | | ||
− | | | + | |Named based on GTS5 book |
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|[[GTS5:NF2-related_schwannomatosis_(NF2)|NF2-related schwannomatosis (NF2)]] | |[[GTS5:NF2-related_schwannomatosis_(NF2)|NF2-related schwannomatosis (NF2)]] | ||
Line 477: | Line 204: | ||
|[[GTS5:Familial_adenomatous_polyposis_(APC)|Familial adenomatous polyposis (APC)]] | |[[GTS5:Familial_adenomatous_polyposis_(APC)|Familial adenomatous polyposis (APC)]] | ||
|Disease | |Disease | ||
+ | |Jennifer Laffin | ||
+ | |8/20/2023 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |MS / LS | ||
| | | | ||
− | | | + | |Named based on GTS5 book |
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|[[GTS5:Gastric_Adenocarcinoma_and_Proximal_Polyposis_of_Stomach_-_GAPPS_(APC_promoter)|Gastric Adenocarcinoma and Proximal Polyposis of Stomach - GAPPS (APC promoter)]] | |[[GTS5:Gastric_Adenocarcinoma_and_Proximal_Polyposis_of_Stomach_-_GAPPS_(APC_promoter)|Gastric Adenocarcinoma and Proximal Polyposis of Stomach - GAPPS (APC promoter)]] | ||
Line 561: | Line 288: | ||
| | | | ||
| | | | ||
− | | | + | |Named based on GTS5 book (page created 12/30/23) |
|- | |- | ||
|[[GTS5:Hereditary_gastric_and_breast_cancer_syndrome_(CDH1,_CTNNA1)|Hereditary gastric and breast cancer syndrome (CDH1, CTNNA1)]] | |[[GTS5:Hereditary_gastric_and_breast_cancer_syndrome_(CDH1,_CTNNA1)|Hereditary gastric and breast cancer syndrome (CDH1, CTNNA1)]] | ||
Line 572: | Line 299: | ||
| | | | ||
| | | | ||
− | | | + | |Named based on GTS5 book (page created 12/30/23) |
|- | |- | ||
|[[GTS5:Hereditary_mixed_polyposis_syndrome_(GREM1)|Hereditary mixed polyposis syndrome (GREM1)]] | |[[GTS5:Hereditary_mixed_polyposis_syndrome_(GREM1)|Hereditary mixed polyposis syndrome (GREM1)]] | ||
Line 727: | Line 454: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |CHAPTER 3 (OXIDATIVE STRESS RESPONSE AND METABOLISM) | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
|- | |- | ||
|[[GTS5:Von_Hippel-Lindau_syndrome_(VHL)|Von Hippel-Lindau syndrome (VHL)]] | |[[GTS5:Von_Hippel-Lindau_syndrome_(VHL)|Von Hippel-Lindau syndrome (VHL)]] | ||
Line 771: | Line 518: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |CHAPTER 4 (CELL CYCLE AND APOPTOSIS PATHWAYS) | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
|- | |- | ||
|[[GTS5:Li-Fraumeni_syndrome_(TP53)|Li-Fraumeni syndrome (TP53)]] | |[[GTS5:Li-Fraumeni_syndrome_(TP53)|Li-Fraumeni syndrome (TP53)]] | ||
Line 781: | Line 548: | ||
| | | | ||
| | | | ||
− | | | + | |Named based on GTS5 book (page created 12/30/23) |
|- | |- | ||
|[[GTS5:Retinoblastoma_syndrome_(RB1)|Retinoblastoma syndrome (RB1)]] | |[[GTS5:Retinoblastoma_syndrome_(RB1)|Retinoblastoma syndrome (RB1)]] | ||
Line 838: | Line 605: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 5 (DNA REPAIR AND GENOMIC STABILITY) |
− | + | | | |
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
|- | |- | ||
− | |[[GTS5: | + | |[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]] |
|Disease | |Disease | ||
| | | | ||
Line 860: | Line 636: | ||
| | | | ||
|- | |- | ||
− | |[[GTS5: | + | |[[GTS5:Muir-Torre_syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Muir-Torre syndrome (MLH1, PMS2, MSH2, MSH6)]] |
|Disease | |Disease | ||
| | | | ||
Line 871: | Line 647: | ||
| | | | ||
|- | |- | ||
− | |[[GTS5: | + | |[[GTS5:Constitutional_mismatch_repair_deficiency_(CMMRD)_syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Constitutional mismatch repair deficiency (CMMRD) syndrome (MLH1, PMS2, MSH2, MSH6)]] |
|Disease | |Disease | ||
+ | |Jennie Thurston | ||
+ | |7/2/2023 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |LS | ||
| | | | ||
+ | |Named based on GTS5 book | ||
+ | |- | ||
+ | |[[GTS5:BRCA-related_cancer_predisposition_syndrome_(BRCA1,_BRCA2)|BRCA-related cancer predisposition syndrome (BRCA1, BRCA2)]] | ||
+ | |Disease | ||
+ | |Constance Albarracin / Katherine Geiersbach | ||
| | | | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Katherine Geiersbach | ||
| | | | ||
− | | | + | |Named based on GTS5 book (page created 12/30/23) |
|- | |- | ||
|[[GTS5:PALB2-related_cancer_predisposition_syndrome_(PALB2)|PALB2-related cancer predisposition syndrome (PALB2)]] | |[[GTS5:PALB2-related_cancer_predisposition_syndrome_(PALB2)|PALB2-related cancer predisposition syndrome (PALB2)]] | ||
|Disease | |Disease | ||
+ | |Constance Albarracin / Katherine Geiersbach / Jun Liao | ||
| | | | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Katherine Geiersbach | ||
| | | | ||
− | | | + | |Named based on GTS5 book (page created 12/30/23) |
− | |||
− | |||
− | |||
|- | |- | ||
|[[GTS5:RAD51-related_cancer_predisposition_syndrome_(RAD51C,_RAD51D)|RAD51-related cancer predisposition syndrome (RAD51C, RAD51D)]] | |[[GTS5:RAD51-related_cancer_predisposition_syndrome_(RAD51C,_RAD51D)|RAD51-related cancer predisposition syndrome (RAD51C, RAD51D)]] | ||
Line 961: | Line 748: | ||
|[[GTS5:Ataxia-telangiectasia_syndrome_(ATM)|Ataxia-telangiectasia syndrome (ATM)]] | |[[GTS5:Ataxia-telangiectasia_syndrome_(ATM)|Ataxia-telangiectasia syndrome (ATM)]] | ||
|Disease | |Disease | ||
+ | |Evin Gulbahce / Katherine Geiersbach | ||
| | | | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Katherine Geiersbach | ||
| | | | ||
− | | | + | |Named based on GTS5 book (page created 12/30/23) |
− | |||
− | |||
− | |||
|- | |- | ||
|[[GTS5:CHEK2-related_hereditary_(breast)_cancer_predisposition_syndrome_(CHEK2)|CHEK2-related hereditary (breast) cancer predisposition syndrome (CHEK2)]] | |[[GTS5:CHEK2-related_hereditary_(breast)_cancer_predisposition_syndrome_(CHEK2)|CHEK2-related hereditary (breast) cancer predisposition syndrome (CHEK2)]] | ||
Line 979: | Line 766: | ||
| | | | ||
| | | | ||
− | | | + | |Named based on GTS5 book (page created 12/30/23) |
|- | |- | ||
|[[GTS5:Nijmegen_breakage_syndrome_(NBN)|Nijmegen breakage syndrome (NBN)]] | |[[GTS5:Nijmegen_breakage_syndrome_(NBN)|Nijmegen breakage syndrome (NBN)]] | ||
Line 1,090: | Line 877: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |CHAPTER 6 (TELOMERE MAINTENANCE) | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
|- | |- | ||
|[[GTS5:Dyskeratosis_congenita_(DKC1,_TERT,_TERC,_TINF2,_Other_IBMFS_genes)|Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]] | |[[GTS5:Dyskeratosis_congenita_(DKC1,_TERT,_TERC,_TINF2,_Other_IBMFS_genes)|Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]] | ||
Line 1,112: | Line 919: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |CHAPTER 7 (EPIGENETIC DRIVERS AND CHROMATIN REMODELLING) | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
|- | |- | ||
|[[GTS5:Beckwith-Wiedemann_spectrum_(IGF2;_CDKN1C)|Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]] | |[[GTS5:Beckwith-Wiedemann_spectrum_(IGF2;_CDKN1C)|Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]] | ||
Line 1,179: | Line 1,006: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 8 (RNA REGULATION) |
− | + | | | |
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
| | | | ||
+ | ----<br /> | ||
+ | |- | ||
+ | |[[GTS5:DICER1-related_tumour_predisposition_syndrome_(DICER1)|DICER1-related tumour predisposition syndrome (DICER1)]] | ||
+ | |Disease | ||
+ | |Jennie Thurston | ||
+ | |7/2/2023 | ||
+ | | | ||
+ | |PENDING | ||
+ | | | ||
+ | |LS | ||
+ | | | ||
+ | |Named based on GTS5 book | ||
|- | |- | ||
|[[GTS5:MicroRNA_processor_tumour_predisposition_syndromes_(DROSHA,_DGCR8)|MicroRNA processor tumour predisposition syndromes (DROSHA, DGCR8)]] | |[[GTS5:MicroRNA_processor_tumour_predisposition_syndromes_(DROSHA,_DGCR8)|MicroRNA processor tumour predisposition syndromes (DROSHA, DGCR8)]] | ||
Line 1,211: | Line 1,058: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |CHAPTER 9 (PROTEIN REGULATION) | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
+ | | | ||
+ | ----<br /> | ||
|- | |- | ||
|[[GTS5:BAP1-related_tumour_predisposition_syndrome_(BAP1)|BAP1-related tumour predisposition syndrome (BAP1)]] | |[[GTS5:BAP1-related_tumour_predisposition_syndrome_(BAP1)|BAP1-related tumour predisposition syndrome (BAP1)]] |
Latest revision as of 13:45, 25 February 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.